Massimiliano Fabbiani is Associate Professor of Infectious Diseases at the Department of Medical Biotechnologies of the University of Siena. His research activity is mainly focused on HIV infection and antiretroviral therapy. In particular, he has participated in clinical trials on antiretroviral therapy and has conducted studies on the efficacy and tolerability of antiretroviral therapy, on the clinical pharmacology of antiretroviral drugs, on the epidemiology and resistance mechanisms of HIV, on adherence to therapy and on comorbidities during HIV infection (with a particular focus on HIV-related neurocognitive disorders). He has also studied the response to vaccinations (anti-influenza, anti-SARS-CoV-2, anti-pneumococcus) in subjects with and without HIV infection. Among the topics covered by his research activities are also infections by hepatitis viruses (HAV, HBV, HCV), SARS-CoV-2 infection, bacterial and fungal infections.
FABBIANI MASSIMILIANO
Presentation
Office hours
Every day by appointment.
Policlinico Le Scotte, IV lotto, piano 0
Curriculum Vitae
Teaching activities
Completion accademic year: 2026/2027
Course year: 1
First cycle degree (DM 270)
ENVIRONMENT AND WORKPLACE PREVENTION TECHNIQUES
A.Y. 2026/2027
Completion accademic year: 2025/2026
Course year: 1
First cycle degree (DM 270)
ENVIRONMENT AND WORKPLACE PREVENTION TECHNIQUES
A.Y. 2025/2026
Completion accademic year: 2024/2025
Course year: 1
First cycle degree (DM 270)
ENVIRONMENT AND WORKPLACE PREVENTION TECHNIQUES
A.Y. 2024/2025
Research
Ultime pubblicazioni:
- Vergori, A., Cervo, A., Roen, A., Gagliardini, R., Clemente, T., Mazzotta, V., et al. (2026). Risk of Developing Low-Level Viral Rebound Among People With HIV Receiving 2- or 3-Drug Regimens: A Case-Control Study Nested in the ICONA Cohort. OPEN FORUM INFECTIOUS DISEASES, 13(5) [10.1093/ofid/ofag250]. - view more
- Ciccullo, A., Iannone, V., Giacomelli, A., Baldin, G., Lagi, F., Sambo, M., et al. (2026). Changes in cardiovascular and metabolic risk scores after switching to DOR/3TC/TDF, DTG/3TC or BIC/FTC/TAF: results from a multicenter Italian cohort. AIDS, 40(7), 962-966 [10.1097/qad.0000000000004468]. - view more
- Ciccullo, A., Baldin, G., Cervo, A., Oreni, L., Mazzitelli, M., Gasparro, G., et al. (2026). ‘Leaving no stones unturned’: up to 10 years results on the effectiveness, tolerability and metabolic safety of dolutegravir+lamivudine (DTG+3TC) as a switch regimen in the ODOACRE cohort. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 81(6) [10.1093/jac/dkag172]. - view more
- Clemente, T., Torkjazi, G., Capra, N., Gagliardini, R., Cattelan, A.M., Lolatto, R., et al. (2026). Durability of lenacapavir in viremic heavily treatment-experienced people with HIV: real-world data from the PRESTIGIO Registry. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 81(1) [10.1093/jac/dkaf415]. - view more
- Micheli, G., Mondi, A., Roen, A., Taramasso, L., Luchetti, I., Mazzotta, V., et al. (2026). Did the COVID-19 pandemic shift the landscape of late HIV diagnosis?. INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 165 [10.1016/j.ijid.2026.108437]. - view more